TrueMark Investments LLC Invests $574,000 in Gilead Sciences, Inc. $GILD

TrueMark Investments LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 4,675 shares of the biopharmaceutical company’s stock, valued at approximately $574,000.

Several other institutional investors and hedge funds also recently made changes to their positions in GILD. Corundum Trust Company INC purchased a new position in Gilead Sciences in the 3rd quarter worth $26,000. Howard Hughes Medical Institute purchased a new stake in Gilead Sciences during the second quarter valued at about $30,000. MTM Investment Management LLC grew its stake in shares of Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 176 shares during the last quarter. Kilter Group LLC purchased a new position in shares of Gilead Sciences in the second quarter worth about $33,000. Finally, Millstone Evans Group LLC increased its holdings in shares of Gilead Sciences by 58.7% in the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 118 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 1.6%

NASDAQ GILD opened at $136.34 on Tuesday. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The stock has a market capitalization of $169.23 billion, a PE ratio of 20.14, a PEG ratio of 1.76 and a beta of 0.36. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The business’s 50-day moving average is $144.32 and its 200 day moving average is $128.89.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the prior year, the company posted $1.90 EPS. Gilead Sciences’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were issued a dividend of $0.82 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date was Friday, March 13th. Gilead Sciences’s dividend payout ratio is currently 48.45%.

Insiders Place Their Bets

In related news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Friday, February 27th. The shares were sold at an average price of $144.79, for a total value of $1,447,900.00. Following the sale, the chief executive officer owned 642,308 shares in the company, valued at $92,999,775.32. The trade was a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the transaction, the insider directly owned 131,779 shares in the company, valued at approximately $19,006,485.17. The trade was a 2.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 299,280 shares of company stock worth $42,820,550. Insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on GILD. Argus increased their target price on Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Deutsche Bank Aktiengesellschaft lifted their price target on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Morgan Stanley boosted their price objective on Gilead Sciences from $150.00 to $171.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Royal Bank Of Canada increased their price objective on Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 11th. Finally, Wolfe Research raised their target price on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $157.62.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.